Renalytix Plc (RNLX)의 가격은 얼마입니까?

Renalytix Plc (RNLX)의 가격은 $0.1502입니다.

Renalytix Plc (RNLX)의 시가 총액은 무엇입니까?

Renalytix Plc (RNLX)의 시가 총액은 $6.43M입니다.

Renalytix Plc (RNLX) 액면분할

Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.

연도	주식 분할	배수	누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

주식 분할

배수

누적 배수

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	누적 배수	국가
GE HealthCare Technologies Inc. GEHC.US	-	US
Pro Medicus Limited PME.AX	-	AU
BrightSpring Health Services, Inc. Common Stock BTSG.US	-	US
Tempus AI, Inc. TEM.US	-	US
Signify Health, Inc. SGFY.US	-	US

회사

주식 분할 횟수

누적 배수

국가